Table 5.
Reports of Vaccine Breakthrough Infection and Proportions of Variants in Vaccinated and Non-Vaccinated Individuals
| Author | Country | Period | Vaccine | Number of Sequenced Data | Result |
|---|---|---|---|---|---|
| Hacisuleyman et al38 | New York City, USA | March 2021 | mRNA-1273 | N=1 | Whole viral genome sequencing revealed E484K |
| McEwen et al39 | Washington state | February 23 and April 27, 2021 | BNT162b2 (n=14), mRNA-1273 (n=19) | N=20 | The proportion of variants of concern: -60% in vaccinated cases -36.7% in non-vaccinated cases -1.63-fold change (p=0.037) |
| Kustin et al40 | Israel | January 23, 2021 to March 7, 2021 | BNT162b2 | N=813 | Increased proportion of the Beta variant compared with non-vaccinated cases |
| The Centers for Disease Control and Prevention14 | USA | January 1–April 30, 2021 | No data | N=555 | No different from the circulating rates of the variants in vaccinated and non-vaccinated individuals |
| Bergwerk et al42 | Israel | January 20, 2021 to April 28 | BNT162b2 | N=33 | Ratio of variants in vaccinated people similar to the prevalence in non-vaccinated people |
| Jacobson et al44 | USA | December 2020 to March 2021 | BNT162b2 and mRNA-1273 | N= 115 | Vaccinated people do not have statistically significantly elevated risk ratios for infection with variants |